Document Type : Original Article

Authors

1 Department of Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

2 Department of Urology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

3 Department of General Surgery, Faculty of Medicine, Zagazig University, Zagazig, Egypt

4 Department of Clinical Oncology, Faculty of Medicine, Assiut University, Assiut, Egypt

5 Department of Clinical Oncology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

Abstract

Background: Gankyrin is an oncoprotein incriminated in cancer growth, invasion, and spread. Snail1 is associated with mesenchymal features acquisition that is related to invasion and metastasis of malignant cells. Isocitrate dehydrogenase 1(IDH1) has been found to be mutated in several cancers, which leads to altered cellular metabolism and tumorgenesis. The present study aimed to assess Gankyrin, Snail1, and IDH1 expression patterns and compare them to clinicopathological and prognostic parameters.
Method: In our prospective cohort study, the samples taken from 60 renal cell carcinoma (RCC) patients were processed, diagnosed, graded, staged, and subjected to immunohistochemistry for Gankyrin, Snail1, and IDH1. The patients were chosen, treated, and followed up from January 2015 to December 2019. Overall survival (OS) and progression-free survival (PFS) were assessed.
Results: High expression levels of Gankyrin were positively associated with high grade (P = 0.003), stage (P = 0.033), and size of the tumor (P = 0.049), in addition to lymph nodes metastasis (P = 0.01), distant metastases (P = 0.007), higher incidence of tumor progression, unfavorable 5-year PFS, and OS rates (P < 0.001). High expression levels of Snail1 were positively associated with high grade (P = 0.004) and stage (P = 0.023) of the tumors, on top of lymph nodes metastasis (P = 0.003), distant metastases (P = 0.002), higher incidence of tumor progression, poorer fiveyear PFS, and OS rates (P < 0.001). High expression levels of IDH1 were negatively associated with low grade (P = 0.002), stage, and size of the tumor and lymph nodes metastasis (P < 0.001), distant metastases (P = 0.041), lower incidence of tumor progression (P = 0.013), better five-year PFS, and OS rates (P < 0.041).
Conclusion: We indicated the associations between poor RCC pathological parameters, unfavorable patients’ outcome, high Gankyrin, high Snail1, and reduced IDH1 expression.

Keywords

How to cite this article:

Kaf RM, Harb OA, Ali MM, Salama N, Baiomy TA, Abdelgawad MI, et al. Clinicopathological and prognostic values of Gankyrin, Snail1, and IDH1 expression in renal cell carcinoma patients. Middle East J Cancer. 2022;13(2):237-46. doi:10.30476/mejc.2021.86762. 1370.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics,
2018. CA Cancer J Clin. 2018;68(1):7-30.
2. Posadas EM, Limvorasak S, Figlin RA. Targeted
therapies for renal cell carcinoma. Nat Rev Nephrol.
2017;13(8):496-511.
3. Choueiri TK, Motzer RJ. Systemic therapy for
metastatic renal-cell carcinoma. N Engl J Med.
2017;376(4):354-66.
4. Wang C, Li Y, Chu CM, Zhang XM, Ma J, Huang H,
et al. Gankyrin is a novel biomarker for disease
progression and prognosis of patients with renal cell
carcinoma. EBioMedicine. 2019;39:255-64. doi:
10.1016/j.ebiom.2018.12.011.
5. Chen J, Bai M, Ning C, Xie B, Zhang J, Liao H, et al.
Gankyrin facilitates follicle stimulating hormonedriven
ovarian cancer cell proliferation through the
PI3K/ AKT/HIF-1alpha/cyclin D1 pathway. Oncogene.
2016; 35(19):2506-17.
6. Meng FD, Li Y, Tian X, Ma P, Sui CG, Fu LY , et al .
Synergistic effects of snail and quercetin on renal cell
carcinoma Caki-2 by altering AKT/mTOR/ERK1/2
signaling pathways. Int J Clin Exp Pathol. 2015;8(6):
6157-68.
7. Andreina BC, Stepan AE, Margaritescu C, Tăisescu
O, Osman A, Simionescu C. Snail and E-cadherin
immunoexpression in clear cell renal cell carcinoma.
Curr Health Sci J. 2019;45(2): 185-9.
8. Laba PL, Wang J, Zhang J. Low level of isocitrate
dehydrogenase 1 predicts unfavorable postoperative
outcomes in patients with clear cell renal cell
carcinoma. BMC Cancer. 2018;18:852.
9. Edges SB, Compton CC. The American joint
committee on Cancer: the 7th edition of the AJCC
cancer staging manual and the future of TNM. Ann
Surg Oncol. 2010;17: 1471-4.
10. Delahunt B, Srigley JR, Egevad L, Montironi R.
International Society of Urological Pathology grading
and other prognostic factors for renal neoplasia. Eur
Urol. 2014; 66:795-8.
11. Wang C, Cheng L. Gankyrin as a potential therapeutic
target for cancer. Invest New Drugs. 2017; 35(5):655-
61.
12. Huang B, Cai W, Wang Q, Shah ET, He Y, Wong KY,
et al. Gankyrin drives malignant transformation of
gastric cancer and alleviates oxidative stress via
mTORC1 activation. Oxid Med Cell Longev.
2018;2018:9480316. doi: 10.1155/2018/9480316.
13. Fu Q, Xu L, Wang Y, Jiang Q, Liu Z, Zhang J, et al.
Tumor-associated macrophage derived interleukin-23
interlinks kidney cancer glutamine addiction with
immune evasion. Eur Urol. 2019 ;75(5):764-765.
14. Sheng Y, Ng CP, Lourie R, Shah ET, He Y, Wong KY,
et al. MUC13 overexpression in renal cell carcinoma
plays a central role in tumor progression and drug
resistance. Int J Cancer. 2017;140(10):2351-63. doi:
10.1002/ijc.30651.
15. Liu Y, Higashitsuji H , Higashitsuji H, Itoh K, Sakurai
T, Koike K et al. Overexpression of gankyrin in mouse
hepatocytes induces hemangioma by suppressing factor
inhibiting hypoxia-inducible factor-1 (FIH-1) and
activating hypoxia-inducible factor-1. Biochem Biophys
Res Commun. 2013; 432(1):22-7.
16. Chapman AM, McNaughton BR. Synthetic proteins
potently and selectively bind the oncoprotein gankyrin,
modulate its interaction with S6 ATPase, and suppress
Gankyrin/MDM2-dependent ubiquitination of p53.
ACS Chem Biol. 2015;10(8): 1880- 6.
17. Song X, Wang J, Zheng T, Song R, Liang Y, Bhatta
N, et al. LBH589 Inhibits proliferation and metastasis
of hepatocellular carcinoma via inhibition of
gankyrin/STAT3/ Akt pathway. Mol Cancer. 2013;
12(1):114.
18. Chattopadhyay A , O'Connor CJ, Zhang F, Galvagnion
C, Galloway WR, Tan YS, et al. Discovery of a smallmolecule
binder of the oncoprotein gankyrin that
modulates gankyrin activity in the cell. Sci Rep. 2016;
6:23732. doi: 10.1038/srep23732.
19. Mikami S, Katsube KI, Oya M, Ishida M, Kosaka T,
Mizuno R, et al. Expression of Snail and Slug in renal
cell carcinoma: E-cadherin repressor Snail is associated
with cancer invasion and prognosis. Lab Invest. 2011;
91(10):1443-58.
20. O'Mahony FC, Faratian D, Varley J, Nanda J,
Theodoulou M, Riddick AC, et al. The use of
automated quantitative analysis to evaluate epithelialto-
mesenchymaltransition associated proteins in clear
cell renal cell carcinoma. PLoS One. 2012;7(2):
e31557. doi:10.1371/journal.pone.0031557.
21. Cai J. Roles of transcriptional factor Snail and adhesion
factor E-cadherin in clear cell renal cell carcinoma.
Exp Ther Med. 2013; 6(6):1489-93.
22. Liu W, Liu Y, Liu H, Zhang W, An H, Xu J. Snail
predicts recurrence and survival of patients with
localized clear cell renal cell carcinoma after surgical
resection. Urol Oncol. 2015; 33(2):69.e1–69.e10.
23. Messai Y, Noman MZ, Derouiche A, Kourda N, Akalay
I, Hasmim M, et al . Cytokeratin 18 expression pattern
correlates with renal cell carcinoma progression: relationship
with Snail. Int J Oncol. 2010; 36(5):1145-54.
24. Liu WS, Chan SH, Chang HT, Li GC, Tu YT, Tseng
HH, et al. Isocitrate dehydrogenase 1-snail axis
dysfunction significantly correlates with breast cancer
prognosis and regulates cell invasion ability. Breast
Cancer Res. 2018;20(1):25. doi: 10.1186/s13058-018-
0953-7.
25. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, et al.
Glioma-derived mutations in IDH1 dominantly inhibit
IDH1 catalytic activity and induce HIF- 1alpha.
Science. 2009; 324:261-5.
26. Chen X , Li Q, Wang C, Xu W, Han L, Liu Y, et al.
Prognostic and diagnostic potential of isocitrate
dehydrogenase 1 in esophageal squamous cell
carcinoma. Oncotarget. 2016; 7:86148-60.
27. Waitkus MS, Diplas BH, Yan H. Isocitrate
dehydrogenase mutations in gliomas. Neuro-Oncology.
2016;18:16-26.
28. Nassereddine S, Lap CJ, Haroun F, Tabbara I. The
role of mutant IDH1 and IDH2 inhibitors in the
treatment of acute myeloid leukemia. Ann Hematol.
2017; 96:1983-91.
29. Bogdanovic E. IDH1 lipid metabolism and cancer:
shedding new light on old ideas. Biochim Biophys
Acta. 2015; 1850:1781-5.
30. Lu J, Holmgren A. Thioredoxin system in cell death
progression. Antioxid Redox Signal. 2012; 17:1738-
47.
31. Dang L, Yen K, Attar EC. IDH mutations in cancer
and progress toward development of targeted
therapeutics. Ann Oncol. 2016; 27:599-608.